VIR Jan 2025 7.500 put
- Simply Wall St.
Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company
Key Insights Significantly high institutional ownership implies Vir Biotechnology's stock price is sensitive to their...
- Business Wire
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
SAN FRANCISCO, October 03, 2024--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.
- Business Wire
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
SAN FRANCISCO, September 10, 2024--Vir Biotechnology Inc. (Nasdaq: VIR) today announced that Jason O’Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O’Byrne will join the Vir Executive Management Team and report directly to the company’s Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA.
